CL2023002578A1 - Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos - Google Patents
Derivados de alfa-d-galatopiranosido triazolil-metil sustituidosInfo
- Publication number
- CL2023002578A1 CL2023002578A1 CL2023002578A CL2023002578A CL2023002578A1 CL 2023002578 A1 CL2023002578 A1 CL 2023002578A1 CL 2023002578 A CL2023002578 A CL 2023002578A CL 2023002578 A CL2023002578 A CL 2023002578A CL 2023002578 A1 CL2023002578 A1 CL 2023002578A1
- Authority
- CL
- Chile
- Prior art keywords
- galatopyranoside
- triazolyl
- derivatives
- methyl substituted
- substituted alpha
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000000802 Galectin 3 Human genes 0.000 abstract 1
- 108010001517 Galectin 3 Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
La presente invención se refiere a los compuestos de la Fórmula (I), en donde A, R1, R2, RP2, RP3 y RP4 son como se describe en la descripción, su preparación, a sales farmacéuticamente aceptables de los mismos, y a su uso como farmacéuticos, a composiciones farmacéuticas que contienen uno o más compuestos de la fórmula (I), y especialmente a su uso como inhibidores de Galectina-3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021055348 | 2021-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023002578A1 true CL2023002578A1 (es) | 2024-03-22 |
Family
ID=80682779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002578A CL2023002578A1 (es) | 2021-03-03 | 2023-08-31 | Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240109930A1 (es) |
| EP (1) | EP4301748A1 (es) |
| JP (1) | JP2024509421A (es) |
| KR (1) | KR20230154221A (es) |
| CN (1) | CN116888113A (es) |
| AU (1) | AU2022228660A1 (es) |
| BR (1) | BR112023017624A2 (es) |
| CA (1) | CA3209917A1 (es) |
| CL (1) | CL2023002578A1 (es) |
| IL (1) | IL305581A (es) |
| MX (1) | MX2023010241A (es) |
| TW (1) | TW202300146A (es) |
| WO (1) | WO2022184755A1 (es) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (sv) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401301D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| BR112015007985A8 (pt) | 2012-10-10 | 2019-08-27 | Galectin Therapeutics Inc | uso do carboidrato galactose denteada para preparação de composições para tratamento de nefropatia diabética e de distúrbios associados, e suas composições |
| JP2015535233A (ja) | 2012-10-31 | 2015-12-10 | ガレクト・バイオテック・エイビイ | ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用 |
| CN104955471A (zh) | 2012-11-15 | 2015-09-30 | 塔夫斯大学 | 使用半乳糖凝集素蛋白抑制剂用于治疗、调节或预防受试者的眼部血管生成或者纤维化的方法、组合物以及试剂盒 |
| US10774102B2 (en) | 2015-01-30 | 2020-09-15 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| CA2971640C (en) | 2015-07-06 | 2020-09-22 | Gilead Sciences, Inc. | Cot modulators and methods of use thereof |
| WO2018209276A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| CN110869378B (zh) | 2017-05-12 | 2023-10-13 | 卡莱克汀科学有限责任公司 | 预防和治疗疾病的化合物及其用途 |
| US11267811B2 (en) | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| US11072626B2 (en) | 2017-10-11 | 2021-07-27 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| AU2018361991A1 (en) | 2017-10-31 | 2020-05-14 | Galectin Sciences, Llc | Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| WO2020104335A1 (en) | 2018-11-21 | 2020-05-28 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| WO2020210308A1 (en) * | 2019-04-10 | 2020-10-15 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| EP3993870A1 (en) | 2019-07-03 | 2022-05-11 | Galecto Biotech AB | Novel galactoside inhibitor of galectins |
| CA3143078A1 (en) | 2019-07-05 | 2021-01-14 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| CN114206892A (zh) | 2019-08-09 | 2022-03-18 | 爱杜西亚药品有限公司 | (2-乙酰氨基)硫代-β-D-吡喃半乳糖苷衍生物 |
| TW202120102A (zh) | 2019-08-09 | 2021-06-01 | 瑞士商愛杜西亞製藥有限公司 | (雜)芳基-甲基-硫代-β-D-吡喃半乳糖苷衍生物 |
| JP2022544248A (ja) | 2019-08-15 | 2022-10-17 | イドーシア ファーマシューティカルズ リミテッド | ２－ヒドロキシシクロアルカン－１－カルバモイル誘導体 |
| CA3148365A1 (en) | 2019-08-29 | 2021-03-04 | Martin Bolli | Alpha-d-galactopyranoside derivatives |
-
2022
- 2022-03-02 WO PCT/EP2022/055224 patent/WO2022184755A1/en active Application Filing
- 2022-03-02 EP EP22708569.3A patent/EP4301748A1/en active Pending
- 2022-03-02 US US18/548,833 patent/US20240109930A1/en active Pending
- 2022-03-02 BR BR112023017624A patent/BR112023017624A2/pt unknown
- 2022-03-02 IL IL305581A patent/IL305581A/en unknown
- 2022-03-02 MX MX2023010241A patent/MX2023010241A/es unknown
- 2022-03-02 TW TW111107565A patent/TW202300146A/zh unknown
- 2022-03-02 AU AU2022228660A patent/AU2022228660A1/en active Pending
- 2022-03-02 JP JP2023552539A patent/JP2024509421A/ja active Pending
- 2022-03-02 KR KR1020237033375A patent/KR20230154221A/ko unknown
- 2022-03-02 CN CN202280017484.3A patent/CN116888113A/zh active Pending
- 2022-03-02 CA CA3209917A patent/CA3209917A1/en active Pending
-
2023
- 2023-08-31 CL CL2023002578A patent/CL2023002578A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022184755A1 (en) | 2022-09-09 |
| EP4301748A1 (en) | 2024-01-10 |
| AU2022228660A1 (en) | 2023-10-19 |
| MX2023010241A (es) | 2023-09-12 |
| TW202300146A (zh) | 2023-01-01 |
| CA3209917A1 (en) | 2022-09-09 |
| KR20230154221A (ko) | 2023-11-07 |
| IL305581A (en) | 2023-10-01 |
| JP2024509421A (ja) | 2024-03-01 |
| US20240109930A1 (en) | 2024-04-04 |
| BR112023017624A2 (pt) | 2023-10-10 |
| CN116888113A (zh) | 2023-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39296A (es) | Azaquinolonas sustituidas inhibidoras de parp y composiciones farmacéuticas que las contienen | |
| BRPI0819328A8 (pt) | Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos | |
| BR112014030173A8 (pt) | Composto derivado de benzimidazol-prolina, e, composição farmacêutica | |
| BR112013011580A2 (pt) | derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep | |
| BRPI1011657A2 (pt) | derivados aminopropiônicos substituídos como inibidores de neprilisina | |
| BR122019010008B8 (pt) | derivados de pirimidina, seu uso, e composição e combinação farmacêuticas | |
| CO6531445A2 (es) | Derivados bencimidazol-imidazol | |
| UY30912A1 (es) | Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso. | |
| AR045901A1 (es) | Glucocorticoesteroides especificos con actividades antiinflamatoria y antialergica,composiciones farmaceuticas que los contienen,y procedimientos para su preparacion, | |
| BRPI0821115A8 (pt) | Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto | |
| BR112014000713A2 (pt) | derivados de indol substituído como moduladores de gama secretase | |
| ECSP099750A (es) | Imidazoquinolinas con propiedades inmunomoduladoras | |
| CL2022003646A1 (es) | Derivados de amidopirimidona | |
| BRPI0513858B8 (pt) | compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende | |
| BR112013023984A2 (pt) | derivados triazolil piperazina e triazolil piperidina substituidos como moduladores de gama secretase | |
| SV2009003199A (es) | Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| CO2018001700A2 (es) | Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos | |
| AR062211A1 (es) | Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas | |
| BRPI0720742B8 (pt) | derivados de heteroaril pirrolidinil e piperidinil cetona, seus usos e composição farmacêutica compreendo os mesmos | |
| BRPI0511999A (pt) | compostos como antagonistas de ccr5 | |
| CU20100157A7 (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| BR112012032748A2 (pt) | "compostos de piridina anelados" | |
| CL2020001817A1 (es) | Moduladores del receptor c5a | |
| MX2022001789A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo. | |
| SA522431777B1 (ar) | مشتقات ألفا -d- جالاكتو بيرانوسيد |